Related Experiment Video
Updated: Nov 11, 2025
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Prostate-specific Membrane Antigen PET in Prostate Cancer.
Courtney Lawhn-Heath1, Ali Salavati1, Spencer C Behr1
1From the Department of Radiology and Biomedical Imaging (C.L.H., S.C.B., T.A.H.) and Helen Diller Family Comprehensive Cancer Center (S.C.B., T.A.H.), University of California San Francisco, 505 Parnassus Ave, M391, San Francisco, CA 94143; Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Md (A.S., S.P.R.); Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, Calif (J.C.); Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany (W.P.F.); Department of Nuclear Medicine, Technical University of Munich, Munich, Germany (M.E.); Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, Australia (L.E.); Prostate Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre, Melbourne, Australia (M.S.H.); and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia (M.S.H.).
Prostate-specific membrane antigen (PSMA) PET imaging offers superior detection rates for prostate cancer staging and recurrence compared to conventional methods. This advanced imaging technique significantly impacts patient management and treatment strategies.
Area of Science:
- Nuclear medicine
- Oncology
- Radiopharmaceutical development
Background:
- Prostate-specific membrane antigen (PSMA) targeted radiopharmaceuticals are crucial for prostate cancer diagnosis.
- PSMA PET imaging demonstrates higher detection rates than conventional imaging modalities.
- This technology influences management decisions in a significant number of prostate cancer cases.
Purpose of the Study:
- To review the development and clinical significance of PSMA PET radiopharmaceuticals.
- To compare PSMA PET agents with other imaging agents like 18F-fluciclovine and 11C-choline.
- To highlight key PSMA PET agents advancing prostate cancer imaging.
Main Methods:
- Narrative review of existing literature on PSMA PET radiopharmaceuticals.
- Comparative analysis of PSMA PET with fluorine 18 fluciclovine and carbon 11 choline.
- Focus on specific PSMA PET agents and their contributions.
Main Results:
- PSMA PET shows improved detection rates in initial staging and biochemical recurrence.
- Management plans are altered in a substantial percentage of patients due to PSMA PET findings.
- Various PSMA PET agents have been developed, enhancing diagnostic capabilities.
Conclusions:
- PSMA PET is a valuable tool for prostate cancer localization and management.
- It offers advantages over conventional imaging and other PET tracers.
- Continued development of PSMA PET agents promises further advancements in prostate cancer imaging.
